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Ipilimumab, an antibody that blocks cytotoxic T lympho-
cyte antigen 4 (CTLA-4), had shown improved overall sur-
vival (OS) for patients with metastatic melanoma. However
predictive biomarkers for clinical benefit have not been
well defined. We aimed to evaluate serum vascular
endothelial growth factor (VEGF) and its association with
clinical benefit and OS for ipilimumab treated advanced
melanoma patients. Sera were collected from 176 patients
treated with ipilimumab at 3 (n=98) or 10 mg/kg (n=68)
from 2005 to 2013. We analyzed serum VEGF at baseline
and at the end of induction (week 12) by Meso Scale Dis-
covery kit. The association VEGF with clinical benefit and
OS was analyzed using Fisher’s exact test and Kaplan-
Meier log-rank test. Pre-treatment VEGF value correlated
with clinical benefit for 157 melanoma patients with the
availability of clinical response at wk24 (p=0.0111) using
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Figure 1 Kaplan Meier curve of overall survival by using 43 pg/ml as the cutoff for baseline VEGF
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any medium, provided the original work is properly cited.43 pg/ml as the cutoff of baseline VEGF value defined by
maximally selected log-rank statistics. High level of soluble
pre-therapy VEGF (≥ 43 pg/ml) in blood was associated
with decreased OS, as compared to low level baseline
VEGF ( < 43 pg/ml) (Median OS 6.6 vs 12.9 months,
p=0.006 for all 176 patients; median OS 7.4 vs 14.3
months, p=0.037 for 3 mg/kg group; median OS 6.2 vs
10.9 months, p=0.048 for 10 mg/kg group, respectively).
High level of soluble VEGF at wk12 was correlated with
OS in all patients as well (p=0.023). There was no correla-
tion between the change of VEGF and clinical outcome.
Serum VEGF may be a predictive biomarker to ipilimumab
treatment, and prospective investigation warranted.
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